Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

EMEA).

One-year findings from one of two ustekinumab Phase 3 trials were presented for the first time at the annual meeting of the American Academy of Dermatology this past Saturday, February 2.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... agents is time-consuming and expensive. Pharmaceutical companies may have ... bind a target molecule before they hit upon a ... Munich led by Professor Dieter Braun, a member of ... a partner in NanoTemper (an LMU spin-off), have now ...
... New ... ... 2010 -- Model N , Inc., the leader in Revenue Management solutions, today ... Model N Revenue Management Suite by allowing business users to rapidly develop contract documents ...
... ... ... ... ...
Cached Biology Technology:A hot road to new drugs 2Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 2Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 3Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 4Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 5Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 2Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 3Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 4Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 5Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 6
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... ALBUQUERQUE, N.M. A credit-card-sized anthrax detection cartridge developed ... small business makes testing safer, easier, faster and cheaper. ... causes anthrax, is commonly found in soils all over ... illness in both humans and animals. The bacteria can ... to B. anthracis may occur through skin ...
(Date:4/17/2014)... need to produce hydrogen sulfide in order to properly ... study from the Center for Craniofacial Molecular Biology at ... Professor Songtao Shi, principal investigator on the project, said ... governs the flow of calcium ions. The essential ions ... osteogenesis, or the creation of new bone tissue, and ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... on the Earth, thriving by filling every nook and ... first arrived on the scene. Now, this ability ... of food sources may play a significant role in ... to the Biodesign Institute,s Bruce Rittmann, Rosa Krajmalnik-Brown, and ...
... a leading supplier of broadband technology and biometrics software,has ... results,for the second quarter of 2008 on Thursday, July ... and CFO Rick Moberg will host the,earnings conference call., ... can be accessed on the,Investor Relations page of our ...
... LSU Health Sciences Center New Orleans has been ... National Center for Research Resources (NCRR), a part of ... Biological Research Excellence (COBRE) grant funds cardiovascular research projects ... successfully compete nationally for research funding. The competitive ...
Cached Biology News:Can microorganisms be a solution to the world's energy problems? 2Can microorganisms be a solution to the world's energy problems? 3Can microorganisms be a solution to the world's energy problems? 4Aware Announces Q2 2008 Earnings Conference Call 2LSUHSC awarded $10M+ COBRE grant 2LSUHSC awarded $10M+ COBRE grant 3LSUHSC awarded $10M+ COBRE grant 4